Sulforaphane vs NAC for "detox" — what each actually does
"Detox" as a consumer category is mostly marketing — the liver and kidneys handle xenobiotic clearance without supplemental help. But two supplements with credible mechanistic and clinical data sit in this space: sulforaphane, a broccoli-sprout isothiocyanate that activates the Nrf2 antioxidant response, and N-acetylcysteine (NAC), the direct cysteine precursor for glutathione synthesis. Both nudge the same downstream system from different upstream points. Their evidence bases and best use-cases are different, and they are not interchangeable.
Quick verdict
| Goal | Better choice | Why |
|---|---|---|
| Acute acetaminophen overdose / liver protection | NAC | FDA-approved standard of care; intravenous NAC is the only intervention with mortality benefit. Sulforaphane has no acute-overdose evidence. |
| Chronic oxidative stress (general) | Sulforaphane | Activates Nrf2, which upregulates dozens of downstream antioxidant and phase-II enzymes — a broader response than glutathione alone. |
| Mucus thinning (chronic bronchitis, COPD) | NAC | FDA-approved as a mucolytic; multiple RCTs at 600 mg twice daily. |
| Airborne pollutant clearance | Sulforaphane | Kensler 2012 Qidong cohort showed accelerated urinary excretion of benzene and acrolein metabolites at 40 mg/day broccoli-sprout extract. |
| OCD, trichotillomania, addiction | NAC | Tier 2–3 trials at 2400–3000 mg/day with positive but modest effects on compulsive behaviours. |
| Cost per effective dose | NAC | Roughly $0.20–0.30/day at 600–1200 mg. Sulforaphane (Avmacol or equivalent) runs $1–2/day. |
How they compare on the things that matter
Mechanism — what they actually do
NAC supplies cysteine, the rate-limiting amino acid for glutathione synthesis. Oral NAC raises plasma cysteine and modestly raises tissue glutathione in deficient states; in the well-fed adult with a normal liver, the effect on basal glutathione is small. Where NAC is unambiguously useful is acute glutathione depletion — acetaminophen overdose, severe oxidative challenge, contrast nephropathy in some protocols.
Sulforaphane works one level up. It binds and inactivates Keap1, freeing Nrf2 to translocate to the nucleus and drive transcription of antioxidant-response-element (ARE) genes. The downstream proteins include glutathione-S-transferases, NAD(P)H quinone dehydrogenase, heme oxygenase-1, and dozens more. The phenotype is a broader, more sustained shift in antioxidant capacity than a single precursor can deliver. Sulforaphane is also a histone deacetylase inhibitor at higher concentrations — relevant to its emerging investigation in autism and certain cancers.
Evidence base
- NAC — Tier 1 for specific indications (acetaminophen overdose, mucolysis), Tier 2 elsewhere. The Cochrane mucolytic review (2019) supports COPD use. The Berk 2014 OCD trial and Grant 2016 trichotillomania trial support behavioural-health use. Recent contrast-nephropathy meta-analyses are mixed; NAC is no longer routinely recommended for that indication.
- Sulforaphane — Tier 2, evidence 3/5. The Kensler 2012 and 2014 Qidong cohort trials in heavily air-polluted China are the strongest pharmacodynamic data — urinary metabolites of benzene and acrolein cleared faster on broccoli-sprout extract. Singh 2014 showed improvement in autism behaviour scores. Clinical replication for general "detox" claims is thin.
Safety and side-effects
NAC at standard oral doses (600–1800 mg/day) is well tolerated; nausea is the most common complaint. Some patients describe a mild "sulfur" taste. Intravenous NAC for acetaminophen overdose has rare anaphylactoid reactions that require monitoring; oral use does not. NAC may interact with nitrate medications (potentiates vasodilation) and is the subject of an ongoing FDA jurisdictional debate (it was approved as a drug in 1963).
Sulforaphane is well tolerated at trial doses. The dominant side effect is mild GI upset and broccoli-related odour. There is a theoretical thyroid-modulating signal at very high cruciferous intakes, but supplemental sulforaphane at the 10–40 mg/day range used in trials has not produced meaningful thyroid signals.
What the price difference buys you
NAC is one of the cheapest evidence-based supplements available — $10–20 for a 60-day supply at 600 mg twice daily. Sulforaphane (Avmacol or a comparable stabilised broccoli-sprout extract) runs $30–60/month at the trial-dose range. The Nrf2-upregulation hypothesis is real, but the practical benefit for an otherwise healthy adult eating cruciferous vegetables is modest.
Who should skip each
NAC is best avoided in active asthma exacerbation (rare bronchospasm) and should be paused 24–48 hours before surgery (theoretical antiplatelet activity). Pregnancy use is supported by data — it is used clinically for acetaminophen toxicity in pregnancy — but routine supplementation in pregnancy is not recommended without clinical reason.
Sulforaphane should be avoided in pregnancy (insufficient safety data) and approached cautiously in patients on warfarin (cruciferous-vegetable vitamin K content varies in extracts). Patients with active iodine-deficient hypothyroidism should be cautious of very-high cruciferous intakes generally.
What we'd actually buy
For mucolytic support during a chronic bronchitis exacerbation or for the OCD/trichotillomania off-label indications: NAC 600–1200 mg twice daily, with food. Pause 24–48 hours before any surgery. Reassess at 8–12 weeks.
For chronic exposure to air pollution, cigarette smoke (your own or environmental), or as adjunct to a real cardiovascular care plan in someone who can't reliably eat 2 cups/day of cruciferous vegetables: sulforaphane (stabilised broccoli-sprout extract) at 10–30 mg/day. Whole broccoli sprouts are an option but standardisation is unreliable.
Sources
- Smilkstein MJ, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. N Engl J Med. 1988;319(24):1557–1562. PMID: 3059186
- Cazzola M, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24(137):451–461. PMID: 26324807
- Kensler TW, et al. Modulation of the metabolism of airborne pollutants by glucoraphanin-rich and sulforaphane-rich broccoli sprout beverages in Qidong, China. Cancer Prev Res. 2012;5(8):1003–1010. PMID: 22689531
- Singh K, et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci U S A. 2014;111(43):15550–15555. PMID: 25313065
- Grant JE, et al. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009;66(7):756–763. PMID: 19581567
- Houghton CA. Sulforaphane: its "coming of age" as a clinically relevant nutraceutical in the prevention and treatment of chronic disease. Oxid Med Cell Longev. 2019;2019:2716870. PMID: 31737167